SHIFTBIO develops a Natural Drug Delivery Platform utilizing AI-powered design for advanced therapeutics. This platform enables the precise targeting and efficient endolysosomal escape of protein and genetic medicines. The technology supports safe re-dosing capabilities to advance drug development pipelines.
Funding
Funding not disclosed
Founders
Product
Problem
Current drug delivery methods often lack precision, leading to systemic toxicity and reduced efficacy, especially in treating rare diseases and cancers. Traditional methods struggle to target specific cells and tissues, resulting in off-target effects and limiting the therapeutic window.
Solution
ShiftBio is developing a natural nanoparticle (NNP) drug delivery platform that leverages exosomes for targeted therapeutic delivery. Their AI-driven platform designs and manufactures NNPs capable of precisely delivering payloads to specific cells and tissues, enhancing treatment efficacy while minimizing off-target effects. By harnessing the inherent biocompatibility and targeting capabilities of exosomes, ShiftBio aims to improve drug bioavailability and reduce systemic toxicity, creating a paradigm shift in drug development. The platform offers a versatile approach applicable to a range of therapeutic modalities, including small molecules, biologics, and gene therapies.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing targeted therapies for rare diseases and cancer.
Features
- NNP Design AI: An artificial intelligence-driven design platform for creating optimized natural nanoparticle drug carriers.
- Precise payload delivery to specific cells and tissues, enhancing treatment efficacy.
- Enhanced biocompatibility and reduced systemic toxicity compared to traditional drug delivery methods.
- Versatile platform applicable to various therapeutic modalities.
- Streamlined manufacturing process for scalable production of NNPs.